Jump to content

Drilldown: Medicines

Choose a table:


Medicines > classes : Classic Psychedelic or Neuroleptic or super-potent)]]

Use the filters below to narrow your results.

generic:
brand:
None (69) · Delysid (historical, Sandoz, withdrawn 1965) (1) · Fanapt (1) · Geodon (1) · Inapsine (1) · Invega (1) · Latuda (1) · Loxitane (1) · Mellaril (1) · Moban (1) · Navane (1) · Orap (1) · Prolixin (1) · Saphris (1) · Stelazine (1) · Temovate, Clobex, Cormax, Olux, Olux-E, Impoyz (1) · Thorazine (1) · Trilafon (1)
classes: (Click arrow to add another value)
mechanism:
5-HT2A agonist (26) · Potent 5-HT2A agonist (5) · LSD analogue; 5-HT2A agonist (4) · Phenothiazine D2 antagonist (4) · Prodrug of LSD; 5-HT2A agonist (4) · Contains LSA (2) · Contains mescaline (2)
uses:
None (85) · '"`UNIQ--vote-0000079C-QINU`"', '"`UNIQ--vote-0000079D-QINU`"' (1)
starting dose:
None (85) · Apply a thin film to affected area BID; '''limit to 2 weeks''' continuous use and ≤50 g/week (cream/ointment); ≤50 mL/week (foam/solution); avoid face, intertriginous areas (1)
preparations:
None (85) · Cream, ointment, lotion, foam, solution, shampoo, spray at 0.025-0.05%; emollient and non-emollient bases (1)
fda max:
None (85) · 50 g/week (cream/ointment); 2-week continuous limit; 4-week maximum cumulative (1)
routes:
None (84) · Oral (1) · Topical (1)
onset:
None (84) · 30–60 minutes (1) · Hours to days for inflammation; substantial improvement within 1 week (1)
duration:
None (84) · 8–12 hours (1) · Hours to days per application (1)
halflife:
None (84) · 3–5 hours (1) · Not meaningfully described for topical use (systemic exposure varies with surface area, occlusion, skin integrity)'"`UNIQ--ref-0000079E-QINU`"' (1)
bioavailability:
None (84) · 70–90% (oral) (1) · Topical with variable systemic absorption depending on body site, occlusion, and skin integrity; HPA-axis suppression is documented even with brief courses to large areas'"`UNIQ--ref-0000079F-QINU`"' (1)
pregnancy:
None (84) · Not established (1) · Topical corticosteroids in pregnancy: use lowest potency and smallest area; super-potent agents like clobetasol are reserved for compelling indications.<sup class="pcp-cn" title="This claim needs a citation.">&#91;[[Pharmacopedia:Citation needed|citation&nbsp;needed]]&#93;</sup> (1)
legal:
None (84) · Schedule I (United States) (1) · [[USLegal:Prescription only|Rx-only]] in US (1)

Showing below up to 86 results in range #1 to #86.

View (previous 250 | next 250) (20 | 50 | 100 | 250 | 500)


View (previous 250 | next 250) (20 | 50 | 100 | 250 | 500)

Retrieved from "https://pharmacopedia.wiki/p/Special:Drilldown/Medicines"